MD3464265T2 - Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină - Google Patents

Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină

Info

Publication number
MD3464265T2
MD3464265T2 MDE20190411T MDE20190411T MD3464265T2 MD 3464265 T2 MD3464265 T2 MD 3464265T2 MD E20190411 T MDE20190411 T MD E20190411T MD E20190411 T MDE20190411 T MD E20190411T MD 3464265 T2 MD3464265 T2 MD 3464265T2
Authority
MD
Moldova
Prior art keywords
methyl
oxopyridin
methoxypyridin
methoxymethyl
carboxamide
Prior art date
Application number
MDE20190411T
Other languages
English (en)
Inventor
Haydn Beaton
David Malcolm Crowe
Hannah Joy Edwards
Nicholas James Griffiths-Haynes
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of MD3464265T2 publication Critical patent/MD3464265T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Invenţia furnizează noi polimorfe de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă şi săruri ale acestora, compoziţii farmaceutice care le conţin, şi utilizarea lor în terapie.
MDE20190411T 2016-06-01 2017-06-01 Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină MD3464265T2 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662344059P 2016-06-01 2016-06-01
GBGB1609607.5A GB201609607D0 (en) 2016-06-01 2016-06-01 Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
PCT/GB2017/051579 WO2017208005A1 (en) 2016-06-01 2017-06-01 Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1 -({4-[2-oxopyridin-1 -yl)methyl]phenyl} methyl) pyrazole -4-carboxamide as kallikrein inhibitors

Publications (1)

Publication Number Publication Date
MD3464265T2 true MD3464265T2 (ro) 2022-12-31

Family

ID=56410856

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190411T MD3464265T2 (ro) 2016-06-01 2017-06-01 Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină

Country Status (25)

Country Link
US (2) US11230537B2 (ro)
EP (2) EP4151630A1 (ro)
JP (2) JP6957516B2 (ro)
KR (1) KR102425918B1 (ro)
CN (1) CN109379891B (ro)
AU (1) AU2017273136B2 (ro)
BR (1) BR112018073521B1 (ro)
CA (1) CA3025720A1 (ro)
DK (1) DK3464265T3 (ro)
ES (1) ES2927779T3 (ro)
GB (1) GB201609607D0 (ro)
HR (1) HRP20221019T1 (ro)
HU (1) HUE059165T2 (ro)
IL (1) IL263222B (ro)
LT (1) LT3464265T (ro)
MA (1) MA45130B1 (ro)
MD (1) MD3464265T2 (ro)
MX (1) MX2018014700A (ro)
PL (1) PL3464265T3 (ro)
PT (1) PT3464265T (ro)
RS (1) RS63604B1 (ro)
RU (1) RU2756273C2 (ro)
SI (1) SI3464265T1 (ro)
WO (1) WO2017208005A1 (ro)
ZA (1) ZA201808638B (ro)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
RU2020140891A (ru) 2016-05-31 2021-02-10 Калвиста Фармасьютикалз Лимитед Производные пиразола в качестве ингибиторов калликреина
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
IL274557B1 (en) 2017-11-29 2024-05-01 Kalvista Pharmaceuticals Ltd Dosage forms containing a plasma kallikrein inhibitor
CA3093802A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
JP2022549601A (ja) 2019-09-18 2022-11-28 武田薬品工業株式会社 ヘテロアリール血漿カリクレインインヒビター
CN114728962A (zh) 2019-09-18 2022-07-08 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
CN111875557B (zh) * 2020-08-19 2023-06-02 南通大学 一种噻唑类衍生物及其合成方法
EP4232031A1 (en) * 2020-10-23 2023-08-30 Kalvista Pharmaceuticals Limited Treatments of angioedema
WO2022172006A1 (en) * 2021-02-09 2022-08-18 Kalvista Pharmaceuticals Limited Treatments of hereditary angioedema

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptide derivatives
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
US7101878B1 (en) 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
RU2260592C9 (ru) 1999-04-15 2017-04-07 Бристол-Маерс Сквибб Ко. Циклические ингибиторы протеинтирозинкиназ
AU784946B2 (en) 1999-12-08 2006-08-03 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
ES2281565T3 (es) 2001-10-26 2007-10-01 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida.
EP1451160B1 (en) 2001-11-01 2010-01-13 Icagen, Inc. Pyrazole-amides for use in the treatment of pain
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
UA79113C2 (en) 2002-04-26 2007-05-25 Lilly Co Eli Triazole derivatives as tachykinin receptor antagonists
EP1426364A1 (en) 2002-12-04 2004-06-09 Aventis Pharma Deutschland GmbH Imidazole-derivatives as factor Xa inhibitors
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
EP1603883B1 (en) 2003-02-03 2012-03-28 Janssen Pharmaceutica NV Quinoline-derived amide modulators of vanilloid vr1 receptor
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
GB0403155D0 (en) 2004-02-12 2004-03-17 Vernalis Res Ltd Chemical compounds
EP1568698A1 (en) 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
PT1784402E (pt) 2004-09-03 2011-08-23 Yuhan Corp Derivados de pirrolo[3,2-c]piridina e processos para a sua preparação
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
GB0508472D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
JP2008539230A (ja) 2005-04-28 2008-11-13 ガレニカ テクノロジー アンチエボラグ 脂質相を含む薬学的投与形態
KR101142363B1 (ko) 2005-06-27 2012-05-21 주식회사유한양행 피롤로피리딘 유도체를 포함하는 항암제 조성물
US7732475B2 (en) 2005-07-14 2010-06-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
GB0606876D0 (en) 2006-04-05 2006-05-17 Glaxo Group Ltd Compounds
US20070258976A1 (en) 2006-05-04 2007-11-08 Ward Keith W Combination Therapy for Diseases Involving Angiogenesis
MX2009000117A (es) 2006-07-06 2009-01-23 Glaxo Group Ltd N-fenilmetil-5-oxo-prolin-2-amidas sustituidas como antagonistas de receptores p2x7 y sus metodos de uso.
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
CA2673580C (en) 2006-12-29 2015-11-24 Abbott Gmbh & Co. Kg Carboxamide compounds and their use as calpain inhibitors
US20100119512A1 (en) 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
WO2008109177A2 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
SG179437A1 (en) 2007-03-30 2012-04-27 Sanofi Aventis Pyrimidine hydrazide compounds as pgds inhibitors
JP2010523524A (ja) 2007-04-03 2010-07-15 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのイミダゾリジンカルボキサミド誘導体
AR067663A1 (es) 2007-07-26 2009-10-21 Syngenta Participations Ag Derivados heterociclicos de etiloxi amidas, composiciones que los comprenden y usos de los mismos en agricultura u horticultura, como agentes antifungicos.
AU2008288897A1 (en) 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009083553A1 (en) 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
WO2009097141A1 (en) 2008-01-31 2009-08-06 Joslin Diabetes Center Methods for treatment of kallikrein-related disorders
WO2009106980A2 (en) 2008-02-29 2009-09-03 Pfizer Inc. Indazole derivatives
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
PL2308838T3 (pl) 2008-07-08 2016-08-31 Daiichi Sankyo Co Ltd Aromatyczne związki heterocyklilowe zawierające azot
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
BR112012014990A2 (pt) 2009-12-18 2016-04-05 Activesite Pharmaceuticals Inc composto, método para tratar uma doença ou condição dependente de calicreína de plasma, e, composição.
JP2011157349A (ja) 2010-01-07 2011-08-18 Daiichi Sankyo Co Ltd 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物
JP5709902B2 (ja) 2010-01-28 2015-04-30 ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー トリプシン様セリンプロテアーゼ阻害剤、ならびにその調製および使用
JP2013121919A (ja) 2010-03-25 2013-06-20 Astellas Pharma Inc 血漿カリクレイン阻害剤
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
EP2458315B1 (de) 2010-11-25 2017-01-04 Balcke-Dürr GmbH Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
BR112013031296B1 (pt) 2011-06-08 2021-02-17 Micro Motion, Inc. sistema de fluxo de fluido, eletrônica de medidor para um sensor vibratório, e, método para operar um sistema de fluxo de fluido
US9133128B2 (en) 2011-06-17 2015-09-15 Research Triangle Institute Pyrazole derivatives as cannabinoid receptor 1 antagonists
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
EP2760828B1 (en) 2011-09-27 2015-10-21 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048982A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
EP2807157A1 (en) 2012-01-27 2014-12-03 Novartis AG 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2013120104A2 (en) 2012-02-10 2013-08-15 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US9846160B2 (en) 2012-02-27 2017-12-19 Board Of Regents, The University Of Texas Systems Ganglioside GD2 as a marker and target on cancer stem cells
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
AR094378A1 (es) 2013-01-08 2015-07-29 Savira Pharmaceuticals Gmbh Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
IL239682B (en) * 2013-01-08 2018-10-31 Kalvista Pharmaceuticals Ltd History of benzylamine and 2-(aminomethyl)pyridine
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
PT2948479T (pt) 2013-01-20 2018-11-14 Dyax Corp Avaliação e tratamento de distúrbios mediados por bradicinina
CA3051327A1 (en) 2013-03-15 2014-09-18 Verseon Corporation Multisubstituted aromatic compounds as serine protease inhibitors
MX363689B (es) * 2013-05-23 2019-03-29 Kalvista Pharmaceuticals Ltd Derivados de heterociclicos.
MX366498B (es) 2013-08-14 2019-07-11 Kalvista Pharmaceuticals Ltd Inhibidores de calicreina plasmatica.
GB2517908A (en) 2013-08-14 2015-03-11 Kalvista Pharmaceuticals Ltd Bicyclic inhibitors
US9611252B2 (en) 2013-12-30 2017-04-04 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds
EA032713B1 (ru) 2013-12-30 2019-07-31 Лайфсай Фармасьютикалс, Инк. Терапевтические ингибирующие соединения
KR102510427B1 (ko) 2014-03-07 2023-03-14 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
WO2015171526A2 (en) 2014-05-05 2015-11-12 Global Blood Therapeutics, Inc. Tricyclic pyrazolopyridine compounds
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
BR112017000816A2 (pt) 2014-07-16 2017-12-05 Lifesci Pharmaceuticals Inc compostos inibitórios terapêuticos
EP3182962B1 (en) 2014-08-22 2023-06-07 Biocryst Pharmaceuticals, Inc. Compositions and uses of amidine derivatives
KR20170048410A (ko) 2014-09-17 2017-05-08 베르선 코포레이션 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물
GB201421088D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
JP2018506563A (ja) 2015-02-27 2018-03-08 ヴァーセオン コーポレイション セリンプロテアーゼ阻害剤としての置換ピラゾール化合物
EP3317241A4 (en) 2015-07-01 2019-01-23 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
WO2017001926A2 (en) 2015-07-01 2017-01-05 Lifesci Pharmaceuticals, Inc Therapeutic inhibitory compounds
EP3368524B1 (en) 2015-10-27 2021-08-18 Boehringer Ingelheim International GmbH Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US10399961B2 (en) 2015-10-27 2019-09-03 Boehringer Ingelheim International Gmbh Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
RU2020140891A (ru) 2016-05-31 2021-02-10 Калвиста Фармасьютикалз Лимитед Производные пиразола в качестве ингибиторов калликреина
GB201609519D0 (en) 2016-05-31 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609603D0 (en) * 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
EP3481391A4 (en) 2016-07-11 2020-03-11 Lifesci Pharmaceuticals, Inc. THERAPEUTIC INHIBITOR COMPOUNDS
GB201713660D0 (en) 2017-08-25 2017-10-11 Kalvista Pharmaceuticals Ltd Pharmaceutical compositions
GB201721515D0 (en) 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor
GB201719882D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of a plasma kallikrein inhibitor and salts thereof
TW201925188A (zh) 2017-11-29 2019-07-01 英商卡爾維斯塔製藥有限公司 酶抑制劑
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
GB201910125D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of angioedema
GB201910116D0 (en) 2019-07-15 2019-08-28 Kalvista Pharmaceuticals Ltd Treatments of hereditary angioedema
CN114206852A (zh) 2019-08-09 2022-03-18 卡尔维斯塔制药有限公司 血浆激肽释放酶抑制剂
CA3147566A1 (en) 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
WO2021032936A1 (en) 2019-08-21 2021-02-25 Kalvista Pharmaceuticals Limited Enzyme inhibitors
BR112022001054A2 (pt) 2019-08-21 2022-03-15 Kalvista Pharmaceuticals Ltd Inibidores enzimáticos
EP4017850A1 (en) 2019-08-21 2022-06-29 Kalvista Pharmaceuticals Limited Enzyme inhibitors
GB201918994D0 (en) 2019-12-20 2020-02-05 Kalvista Pharmaceuticals Ltd Treatments of diabetic macular edema and impaired visual acuity

Also Published As

Publication number Publication date
EP4151630A1 (en) 2023-03-22
CN109379891B (zh) 2022-04-26
EP3464265A1 (en) 2019-04-10
AU2017273136B2 (en) 2021-07-08
CN109379891A (zh) 2019-02-22
HRP20221019T1 (hr) 2022-11-11
MX2018014700A (es) 2019-02-28
MA45130B1 (fr) 2022-10-31
PL3464265T3 (pl) 2022-11-07
IL263222A (en) 2018-12-31
LT3464265T (lt) 2022-11-10
JP6957516B2 (ja) 2021-11-02
US11739068B2 (en) 2023-08-29
JP7383676B2 (ja) 2023-11-20
JP2022003083A (ja) 2022-01-11
SI3464265T1 (sl) 2022-09-30
DK3464265T3 (da) 2022-08-22
KR102425918B1 (ko) 2022-07-26
RU2756273C2 (ru) 2021-09-29
RU2018139276A3 (ro) 2020-10-07
CA3025720A1 (en) 2017-12-07
MA45130A (fr) 2019-04-10
AU2017273136A1 (en) 2018-11-29
RS63604B1 (sr) 2022-10-31
IL263222B (en) 2022-09-01
GB201609607D0 (en) 2016-07-13
US20220041571A1 (en) 2022-02-10
JP2019517463A (ja) 2019-06-24
PT3464265T (pt) 2022-10-20
US11230537B2 (en) 2022-01-25
HUE059165T2 (hu) 2022-10-28
WO2017208005A1 (en) 2017-12-07
BR112018073521A2 (pt) 2019-03-19
US20200317633A1 (en) 2020-10-08
KR20190033485A (ko) 2019-03-29
ZA201808638B (en) 2019-09-25
ES2927779T3 (es) 2022-11-10
RU2018139276A (ru) 2020-07-10
EP3464265B1 (en) 2022-07-13
BR112018073521B1 (pt) 2024-02-06

Similar Documents

Publication Publication Date Title
MD3464265T2 (ro) Polimorfi de N-[(3-fluoro-4-metoxipiridin-2-il)metil]-3-(metoximetil)-1-({4-[2-oxopiridin-1-il)metil]fenil}metil)pirazol-4-carboxamidă ca inhibitori de kalicreină
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
MX2022004304A (es) Agentes inductores de apoptosis.
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
UY34161A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen
EA201691302A1 (ru) Новые гетероциклические соединения
EA201691134A1 (ru) Новые ингибиторы глутаминазы
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
TR201909353T4 (tr) Multipl skleroz tedavisi.
EA201591781A1 (ru) Химические соединения
EA201692474A1 (ru) Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
EA202090572A1 (ru) ИНГИБИТОРЫ Rho-АССОЦИИРОВАННОЙ, СОДЕРЖАЩЕЙ СУПЕРСПИРАЛЬ ПРОТЕИНКИНАЗЫ
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
EA202091711A1 (ru) ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
CL2017001478A1 (es) Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr)